SCHEMBL15565832

SCHEMBL15565832

COC(=O)c1ccc(COc2ccc(CC=O)cc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.69
MAPT P10636 6/20 0.69
NPC1 O15118 5/20 0.69
SMN1; SMN2 Q16637 5/20 0.69
MEN1 O00255 2/20 0.69
KMT2A Q03164 2/20 0.69
LMNA P02545 1/20 0.57
POLB P06746 1/20 0.55
RXRA P19793 1/20 0.55
RXRB P28702 1/20 0.55
ALDH1A1 P00352 3/20 0.55
PKM P14618 1/20 0.55
HTT P42858 2/20 0.55
KDM4E B2RXH2 1/20 0.54
FFAR1 O14842 1/20 0.53
PARP10 Q53GL7 1/20 0.53
CTSK P43235 1/20 0.52
PTPRC P08575 1/20 0.51
PTPN2 P17706 1/20 0.51
PTPN1 P18031 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11350421 0.91 RAB9A (0.82) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL10236929 0.91 RAB9A (0.82) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL223801 0.87 LOXL2 (0.63) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL18259961 0.87 NPC1 (0.73) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL10464779 0.87 NPC1 (0.73) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL3729907 0.86 NPC1 (0.75) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL12086470 0.86 RAB9A (0.80) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL11363883 0.84 RAB9A (0.73) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL6959174 0.84 NPC1 (0.73) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL898771 0.84 RXRA (0.77) RAB9AMAPTNPC1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2882740-B1 IAP ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2017-03-01 EP disclosed
EP-2882740-B1 IAP ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2017-03-01 EP disclosed
US-9453048-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2016-09-27 US disclosed
US-9453048-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2016-09-27 US disclosed
US-9453048-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2016-09-27 US disclosed
US-20150225452-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2015-08-13 US disclosed
US-20150225452-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2015-08-13 US disclosed
US-20150225452-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2015-08-13 US disclosed
EP-2882740-A1 IAP ANTAGONISTS Bristol-Myers Squibb Company (US) 2015-06-17 EP disclosed
WO-2014025759-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-02-13 WO disclosed
WO-2014025759-A1 IAP ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225452-A1 IAP ANTAGONISTS XIAP, API5, BIRC5 RAB9A 1699/4885MAPT 2673/4885NPC1 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.